Review
Pharmacology & Pharmacy
Lukas Van Melkebeke, Hannelie Korf, Emmanuel A. Tsochatzis, Schalk van der Merwe, Frederik Nevens, Jef Verbeek
Summary: The review highlights the challenges and needs in the treatment of severe alcoholic hepatitis, emphasizing the urgency for more personalized use of corticosteroids and the development of alternative therapeutic strategies.
CURRENT OPINION IN PHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Lucija Virovic-Jukic, Dominik Ljubas, Sanja Stojsavljevic-Shapeski, Neven Ljubicic, Tajana Filipec Kanizaj, Ivana Mikolasevic, Ivica Grgurevic
Summary: Severe alcoholic hepatitis has limited treatment options and poor outcomes with current supportive medical care and corticosteroids. While new treatment options like granulocyte colony-stimulating factor and stem cell transplantation are being explored, evidence for their efficacy remains scarce and further research is needed. Insights into the pathogenesis of AH and liver regeneration processes are crucial for the development of new treatment options, but high-quality studies and reliable experimental models are lacking.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Gyongyi Szabo, Mack Mitchell, Craig J. McClain, Srinivasan Dasarathy, Bruce Barton, Arthur J. McCullough, Laura E. Nagy, Aimee Kroll-Desrosiers, David Tornai, Hyesung Alice Min, Svetlana Radaeva, M. E. Blair Holbein, Lisa Casey, Jennifer Cuthbert
Summary: Combination therapy of anakinra, pentoxifylline, and zinc provides similar survival benefits compared to corticosteroid therapy in severe alcohol-associated hepatitis.
Review
Pharmacology & Pharmacy
Yi Lu, Hao Su, Jianzhong Zhang, Yutao Wang, Hongjun Li
Summary: The systematic review found that PTX is effective in improving sperm motility and morphology in male infertility, as well as in treating erectile dysfunction.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Surgery
Giacomo Germani, Debora Angrisani, Giovanni Addolorato, Manuela Merli, Chiara Mazzarelli, Claudia Tarli, Barbara Lattanzi, Adelaide Panariello, Paola Prandoni, Lucia Craxi, Giovanni Forza, Alessandra Feltrin, Andrea Ronzan, Paolo Feltracco, Antonio Grieco, Salvatore Agnes, Antonio Gasbarrini, Massimo Rossi, Luciano De Carlis, D'Amico Francesco, Umberto Cillo, Luca S. Belli, Patrizia Burra
Summary: This study assessed the outcomes of early liver transplantation (eLT) in patients with severe alcoholic hepatitis (sAH) and found that eLT significantly improved survival in non-responders to medical therapy, when a strict selection process was applied.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Editorial Material
Gastroenterology & Hepatology
Gi Soo Youn, Ki Tae Suk
Summary: This article is linked to Kim et al paper.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Public, Environmental & Occupational Health
Jinyu Liu, Min Guo, Lei Ke, Ruxu You
Summary: The economic evaluation of elbasvir/grazoprevir (EBR/GZR) for chronic hepatitis C (CHC) shows that EBR/GZR may be cost-effective or dominant compared with pegylated interferon and ribavirin (PegIFN/RBV) and other direct antiviral agents (SOF/VEL, 3D, DCV/ASV, LDF/SOF) or non-therapy. However, in certain scenarios, EBR/GZR is not a cost-effective option for CHC patients compared to glecaprevir/pibrentasvir (GLE/PIB).
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Nutrition & Dietetics
Qinjian Wang, Jiangmin Shi, Min Zhao, Gaoyi Ruan, Zebin Dai, Yilang Xue, Dibang Shi, Changlong Xu, Ouyue Yu, Fangyan Wang, Zhanxiong Xue
Summary: This meta-analysis suggests that microbial agents have therapeutic potential for alcoholic liver disease (ALD) by improving liver function and interfering with lipid metabolism, relieving inflammatory response, and inhibiting oxidative stress through modulating the gut microbiota.
FRONTIERS IN NUTRITION
(2022)
Review
Virology
Filippo Gabrielli, Francesco Alberti, Cristina Russo, Carmela Cursaro, Hajrie Seferi, Marzia Margotti, Pietro Andreone
Summary: Hepatitis A and hepatitis E are common causes of liver disease transmitted through the faecal-oral route. Both viruses can cause acute disease with mild liver injury, but severe disease or chronic manifestations can occur in vulnerable patients. Treatment mainly focuses on supportive measures, with limited evidence for aetiological treatment and additional agents in severe cases. Corticosteroid therapy and certain molecules have shown potential for improving outcomes in HAV infection, while ribavirin is the main therapeutic option for HEV infection. Vaccines for HAV have been successful in reducing disease prevalence, and vaccines for HEV are currently being developed.
Letter
Gastroenterology & Hepatology
Benjamin Buchard, Luc Sevigne, Claude Darcha, Leon Muti, Juliette Joubert, Armand Abergel
Summary: The article is linked to the paper by Forrest et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Multidisciplinary Sciences
Xinyu Liang, Yuzhen Wang, Cheng Zhao, Yemin Cao
Summary: This study evaluated the efficacy and safety of cilostazol, pentoxifylline, and beraprost for intermittent claudication caused by lower extremity arterial occlusive disease. The results showed that cilostazol had the best effect on walking distance, followed by beraprost and pentoxifylline. In terms of ankle-brachial index, beraprost and cilostazol combined with beraprost had more significant effects.
Review
Plant Sciences
Nian Liu, Jiayao Yang, Wei Ma, Chenyu Li, Liu An, Xiao Zhang, Qi Zou
Summary: XYP, a Chinese herbal formula, has been found to effectively and safely treat NAFLD. However, further studies are needed to confirm these findings due to the limited number of articles and the lower quality of the studies.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yubing Li, Xinyu Deng, Xiaochuan Guo, Fangling Zhang, Hefei Wu, Xuhua Qin, Xiao Ma
Summary: This study explored the preclinical and clinical evidence of soybeans in alleviating non-alcoholic fatty liver disease (NAFLD). The results showed that soybean could protect the liver in NAFLD by regulating lipid metabolism and oxidative stress factors via the Akt/AMPK/PPARα signaling pathway, making it a promising therapeutic agent for treating NAFLD.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Cell Biology
Luca Cristin, Amalia Montini, Alessandro Martinino, Juan Pablo Scarano Pereira, Francesco Giovinazzo, Salvatore Agnes
Summary: Diabetic and obese patients are highly likely to have non-alcoholic fatty liver disease (NAFLD). Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) play important roles in the development of NAFLD and could be used as therapeutic strategies to prevent NAFLD progression to non-alcoholic steatohepatitis (NASH).
Article
Gastroenterology & Hepatology
Soon Sun Kim, Jung Woo Eun, Hyo Jung Cho, Do Seon Song, Chang Wook Kim, Young Seok Kim, Sung Won Lee, Yoon-Keun Kim, Jinho Yang, Jinhee Choi, Hyung Joon Yim, Jae Youn Cheong
Summary: Dysbiosis was confirmed in severe alcoholic hepatitis, however, it was alleviated by rifaximin treatment. Taxa associated with severe AH could serve as candidate biomarkers or therapeutic targets.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)